CEO of Oncoinvent, Jan A. Alfheim, will be presenting the company at ABGSC Norwegian Oncology Seminar November 23 at 12:50
The aim of this study was to estimate the absorbed doses to normal tissues for patients injected intraperitoneally with a suspension of radium-224 adsorbed in calcium carbonate microparticles (224Ra-CaCO3-MP) for treating peritoneal carcinomatosis originating from colorectal cancer.
CEO, Jan A. Alfheim, will be speaking at the LSX Nordic Biotech Congress and host 1-on-1 meetings with investors on 6-7 September, 2022
First patient has been treated in the RAD-18-002 phase 2A clinical study
All dose levels of Radspherin® were well tolerated with a maximum dose level toxicity not reached in the RAD-18-002 study.
Radspherin® is currently being evaluated in two ongoing Phase 1 trials for the treatment of peritoneal carcinomatosis from ovarian cancer and colorectal cancer
Oncoinvent would like to extend an invitation to a presentation of the Q1 2022 results. The presentation will be held on Wednesday 1. June 2022 at 08:30 AM in the offices of the company at Gullhaugsveien 7, Oslo, 3rd Floor. To attend, please register with firstname.lastname@example.org. Oncoinvent ønsker med dette å invitere til presentasjon av … Read more
CEO, Jan A. Alfheim, will present Oncoinvent at the DNB Small & Medium Enterprises Conference and host 1-on-1 meetings with investors on April 7, 2022
Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that members of management will participate in two upcoming virtual investor conferences: